The HIV-infected patients are co-infected with many bacterial infections in which tuberculosis is most common found worldwide. These patients are often administered with combined therapy of anti-retroviral and anti-tubercular drugs which leads to several complications including hepatotoxicity or adverse drug interactions. The drug-drug interactions between the anti-retroviral and anti-tubercular drugs are not clearly defined and hence, this study was conducted to evaluate the pharmacokinetic drug-drug interactions of Zidovudine (AZT) with Isoniazid (INH) and its hepatotoxic metabolites. Seventy two rats were randomly divided into two major groups with their sub-groups each comprising 6 animals. The Group I received INH alone at a dose of 25 mg/kg; b.w and Group II received AZT (50 mg/kg; b.w) along with INH orally. Pharmacokinetic studies of INH and its metabolites i.e., acetyl hydrazine (ACHY) and hydrazine (HYD) shows that INH and ACHY attains maximum plasma concentration (Cmax) within 30 minutes and HYD attains Cmax at 1 hour after INH administration and all these analytes disappear from plasma within 4 hours. Pharmacokinetic studies also revealed that AZT treatment did not showed any drug-drug interactions and have no effect on the T1/2, plasma clearance, AUC, Cmax and Tmax of INH and its hepatotoxic metabolites.
AnandACSethAKPaulM, et al.Risk factors of hepatotoxicity during anti-tuberculosis treatment. Med J Armed Forces India. 2006;62(1):45–49.
3.
World Health Organization. An evaluation of the impact of early initiation of highly active anti-retroviral therapy (HAART) on tuberculosis (TB) treatment outcomes for TB patients co-infected with human immunodeficiency virus (HIV) [ISRCTN77861053]. 2011. Current Controlled Trials (online). http://www.controlledtrials.com. Accessed October 9, 2011.
4.
YarchoanRKleckerRWWeinholdKJ, et al.Administration of 3′-azido-3′-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet. 1986;1(8481):575–580.
5.
FischlMARichmanDDGriecoMH, et al.The efficacy of azidothymidine (Azt) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317(4):185–191.
6.
DubinGBraffmanMN. Zidovudine-induced hepatotoxicity. Ann Intern Med. 1989;110(1):85–86.
7.
ShahI. Adverse effects of antiretroviral therapy in HIV-1 infected children. J Trop Pediatr. 2006;52(4):244–248.
8.
AcostaBSGrimsleyEW. Zidovudine-associated type B lactic acidosis and hepatic steatosis in an HIV-infected patient. South Med J. 1999;92(4):421–423.
9.
PilheuJADe SalvoMCKochO, et al.Light and electron microscopical studies of the liver of tuberculosis patients receiving rifampicin and isoniazid. Medicina (B Aires). 1981;41(4):439–445.
10.
ZuberPLMcKennaMTBinkinNJ, et al.Long-term risk of tuberculosis among foreign-born persons in the United States. JAMA. 1997;278(4):304–307.
11.
DeanGLEdwardsSGIvesNJ, et al.Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS. 2002;16(1):75–83.
12.
RaghuRKarthikeyanS. Zidovudine and isoniazid induced liver toxicity and oxidative stress: evaluation of mitigating properties of silibinin. Environ Toxicol Pharmacol. 2016;46:217–226.
13.
RaghuRJesudasBBhavaniG, et al.Silibinin mitigates zidovudine-induced hepatocellular degenerative changes, oxidative stress and hyperlipidaemia in rats. Hum Exp Toxicol. 2015;34(11):1031–1042.
14.
HarlassFE. The pharmacology of zidovudine. Infect Dis Update. 1996;3(3):58–62.
15.
VictorrajmohanCPradeepKKarthikeyanS. Influence of silymarin administration on hepatic glutathione-conjugating enzyme system in rats treated with antitubercular drugs. Drugs R D. 2005;6(6):395–400.
16.
GhoshMN. Fundamentals of Experimental Pharmacology. 2nd ed. Calcutta, India: Scientific Book Agency; 1984:216.
17.
SeifartHIGentWLParkinDP, et al.High-performance liquid chromatographic determination of isoniazid, acetylisoniazid and hydrazine in biological fluids. J Chromatogr B Biomed Appl. 1995;674(2):269–275.
18.
AwodeleOAgbajeEOAdesinaEA, et al.Hepatoprotective role of neutrosecR on hepatic damage induced by combination of zidovudine and combined anti-tuberculous agents in rats. Tokai J Exp Clin Med. 2011;36(2):31–36.
19.
KoulAArnoultELounisN, et al.The challenge of new drug discovery for tuberculosis. Nature. 2011;469(7331):483–490.
20.
MetushiIGCaiPZhuX, et al.A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin Pharmacol Ther. 2011;89(6):911–914.
21.
MitchellJRZimmermanHJIshakKG, et al.Isoniazid liver injury: clinical spectrum, pathology, and probable pathogenesis. Ann Intern Med. 1976;84(2):181–192.
22.
PreziosiP. Isoniazid: metabolic aspects and toxicological correlates. Curr Drug Metab. 2007;8(8):839–851.
23.
PetriWAJr. Chemotherapy of microbial diseases: chemotherapy of tuberculosis, Mycobacterium avium complex disease and leprosy. In: BruntonLLLazoJSParkerKL eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 11th ed. New Delhi, India: McGraw Hill Medical Publishing Division, Inc; 2006:1203–1223; Chap 47.
24.
SarichTCAdamsSPZhouT, et al.Isoniazid-induced hepatic necrosis and steatosis in rabbits: absence of effect of gender. Can J Physiol Pharmacol. 1997;75(9):1108–1111.
25.
WhitehouseLWTryphonasLPaulCJ, et al.Isoniazid-induced hepatic steatosis in rabbits: an explanation for susceptibility and its antagonism by pyridoxine hydrochloride. Can J Physiol Pharmacol. 1983;61(5):478–487.
26.
NelsonSDHinsonJAMitchellJR. Application of chemical ionization mass spectrometry and the twin-ion technique to better define a mechanism in acetylhydrazine toxicity. Biochem Biophys Res Commun. 1976;69(4):900–907.
27.
EvansDA. Genetic variations in the acetylation of isoniazid and other drugs. Ann N Y Acad Sci. 1968;151(2):723–733.
28.
SarichTCZhouTAdamsSP, et al.A model of isoniazid-induced hepatotoxicity in rabbits. J Pharmacol Toxicol Methods. 1995;34(2):109–116.
29.
MooreKHRaaschRHBrouwerKL, et al.Pharmacokinetics and bioavailability of zidovudine and its glucuronidated metabolite in patients with human immunodeficiency virus infection and hepatic disease (AIDS Clinical Trials Group protocol 062). Antimicrob Agents Chemother. 1995;39(12):2732–2737.
30.
TikooKTamtaAAliIY, et al.Tannic acid prevents azidothymidine (AZT)-induced hepatotoxicity and genotoxicity along with change in expression of PARG and histone H3 acetylation. Toxicol Lett. 2008;177(2):90–96.
31.
MajidSKhandujaKLGandhiRK, et al.Influence of ellagic acid on antioxidant defense system and lipid peroxidation in mice. Biochem Pharmacol. 1991;42(7):1441–1445.
32.
BanerjeeAAbdelmegeedMAJangS, et al.Zidovudine (AZT) and hepatic lipid accumulation: implication of inflammation, oxidative and endoplasmic reticulum stress mediators. PLoS One. 2013;8(10):e76850.
33.
RamanathanRSivanesanK. Evaluation of ameliorative ability of silibinin against zidovudine and isoniazid-induced hepatotoxicity and hyperlipidaemia in rats: role of silibinin in phase I and II drug metabolism. Chem Biol Interact. 2017;273:142–153.
34.
WuJWLinLCHungSC, et al.Hepatobiliary excretion of silibinin in normal and liver cirrhotic rats. Drug Metab Dispos. 2008;36(3):589–596.
35.
TimbrellJAWrightJMBaillieTA. Monoacetylhydrazine as a metabolite of isoniazid in man. Clin Pharmacol Ther. 1977;22(5 pt 1):602–608.
36.
Indinavir Pharmacokinetics Study Group. Indinavir (MK 639) drug interactions studies. Program and abstracts of the XI International AIDS Conference. Vancouver, British Columbia, 7-12 July 1996; 1996. Abstract MoB174.
37.
Van OosterhoutJJDzinjalamalaFKDimbaA, et al.Pharmacokinetics of anti-tuberculosis drugs in HIV-positive and HIV-negative adults in Malawi. Antimicrob Agents Chemother. 2015;59(10):6175–6180.
